Journal of Gastrointestinal Cancer

, Volume 43, Issue 4, pp 541–546 | Cite as

Treatment of Chemotherapy-Induced Nausea and Vomiting

  • Hanane Inrhaoun
  • Tamás Kullmann
  • Ibrahim Elghissassi
  • Hind Mrabti
  • Hassan Errihani
Review Article



Recent improvements in medical oncology include both development of anticancer and supportive therapy. Serotonin receptor antagonists were introduced in clinical practice 20 years ago. Since then, the prevention and treatment of chemotherapy-induced nausea and vomiting allows continuing efficacious chemotherapy that earlier had to be stopped sometimes for intolerance.


This anniversary review summarises the current antiemetic arsenal focussing on the most potent antiemetic drugs such as serotonin and substance P receptor antagonists.


Antiemetic treatment improves quality of life under chemotherapy and contributes to the survival benefit as well. In spite of the use of these new drugs, a significant number of patients still experience nausea and vomiting. Special complications like delayed emesis can be alleviated by combination therapies.


Prevention and optimal management of chemotherapy-induced nausea and vomiting should be a goal for most patients receiving emetogenic chemotherapy.


Antiemetic Chemotherapy Nausea-vomiting 


  1. 1.
    Glare PA, Danwoodie D. Drugs. 2008;68(18):2575–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Herrstedt J. Nat Clin Pract Oncol. 2008;5(1):32–43.PubMedCrossRefGoogle Scholar
  3. 3.
    Baines MJ. ABC of palliative care. Nausea, vomiting, and intestinal obstruction. BMJ. 1997;315(7116):1148–50.PubMedCrossRefGoogle Scholar
  4. 4.
    Mannix KA. Palliation of nausea and vomiting. CME Can Med. 2002;1(1):18–22.Google Scholar
  5. 5.
    Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 329:1790–96.Google Scholar
  6. 6.
    Cubeddu LX. Oncology. 1996;53 Suppl 1:18–25.PubMedCrossRefGoogle Scholar
  7. 7.
    Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol. 1999;17:338–43.PubMedGoogle Scholar
  8. 8.
    Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer. 2001;9(5):350–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Markman M. Progress in preventing chemotherapy-induced nausea and vomiting. Cleve Clin J Med. 2002;69(8):609–17.PubMedCrossRefGoogle Scholar
  10. 10.
    Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol. 2007;61:162–75.PubMedCrossRefGoogle Scholar
  11. 11.
    Réseau Oncolor Référenciels Anti-nauséeux et anti-émétiques [en ligne], 2003.Google Scholar
  12. 12.
    Toth J, Szanto J. Magy Oncol. 2008;52(4):391–4.CrossRefGoogle Scholar
  13. 13.
    NCCN. National Comprehensive Cancer Network: Antiemesis, Clinical Practice Guidelines in Oncology-v.1. 2010. (4 October 2010, date last accessed).
  14. 14.
    Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006;17:20–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Basch E, Prestrud AA, Hesketh PJ. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2011;29(31):4189–98.PubMedCrossRefGoogle Scholar
  16. 16.
    Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482–94.PubMedCrossRefGoogle Scholar
  17. 17.
    Dewit R. Br J Cancer. 2003;88(12):1823–7.CrossRefGoogle Scholar
  18. 18.
    Geling O, Eichler H. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23:1289–94.PubMedCrossRefGoogle Scholar
  19. 19.
    Lindley C, Blower P. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health-Syst Pharm 57 (18): 1685–97.Google Scholar
  20. 20.
    Kast RE. European Journal of Cancer Care. 2007;16:351–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Benedict CR, Arbogast R, Martin L, et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol. 1996;28:53–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Shadle CR. J Clin Pharmacol. 2004;44:215–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Depre M, Van Hecken A, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol. 2005;61:341–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Velasco M, Luchsinger A. Dopamine: pharmacologic and therapeutic aspects. Am J Ther. 1998;5(1):37–43.PubMedCrossRefGoogle Scholar
  25. 25.
    Laszlo J, Clark RA, Hanson DC, et al. Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic, amnesic and anxiolytic effects. J Clin Oncol. 1985;3:864–9.PubMedGoogle Scholar
  26. 26.
    Tramèr MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323:16–21.PubMedCrossRefGoogle Scholar
  27. 27.
    Sledge Jr GW, Einhorn L, Nagy C, et al. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer. 1992;70(10):2524–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998;55(2):173–89.PubMedCrossRefGoogle Scholar
  29. 29.
    Lofters WS, Pater JL, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997;15(8):2966–73.PubMedGoogle Scholar
  30. 30.
    Fedele P, Spina M, Valentini M, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer. 1995;76(3):535–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Noda K, Ikeda M, Yoshida O. Clinical evaluation of Ramosetron injections in the treatment of cisplatin-induced nausea and vomiting. J Int Med Res. 2002;30(3):211–9.PubMedGoogle Scholar
  32. 32.
    Voravud N, Sriuranpong V. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting. J Med Assoc Thai. 2005;88(12):1790–6.PubMedGoogle Scholar
  33. 33.
    Koizumi W, Tanabe S, Nagaba S, et al. A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint? Chemotherapy. 2003;49(6):316–23.PubMedCrossRefGoogle Scholar
  34. 34.
    Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in reventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17(9):1441–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14(10):1570–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Palonosetron Study Group Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98(11):2473–82.PubMedCrossRefGoogle Scholar
  37. 37.
    Smyth JF, Coleman RE, Nicolson M, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ. 1991;303(6815):1423–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing, efficacy, and tolerability analysis. Ann Oncol. 2007;18:233–40.PubMedCrossRefGoogle Scholar
  39. 39.
    Münstedt K, Müller H, Blauth-Eckmeyer E, et al. Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting. Br J Cancer. 1999;79(3–4):637–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Gralla RJ, de Wit R, Herrstedt J, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer. 2005;104(4):864–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol. 2011;29(11):1495–501.PubMedCrossRefGoogle Scholar
  42. 42.
    Navari RM. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities. Curr Opin Investig Drugs. 2008;9(7):774–85.PubMedGoogle Scholar
  43. 43.
    Roila F, Herrstedt J, Aapro M. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(l5):v232–43.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Hanane Inrhaoun
    • 1
  • Tamás Kullmann
    • 2
  • Ibrahim Elghissassi
    • 1
  • Hind Mrabti
    • 1
  • Hassan Errihani
    • 1
  1. 1.Department of Medical OncologyNational Institute of OncologyRabatMorocco
  2. 2.Department of Medical OncologySaint Louis HospitalParisFrance

Personalised recommendations